The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Open accessAbstract
Multiple, complex molecular events characterize cancer development and progression. Deciphering the molecular networks that distinguish organ-confined disease from metastatic disease may lead to the identification of critical biomarkers for cancer invasion and disease aggressiveness. Although gene and protein expression have been extensively profiled in human tumours, little is known about the global metabolomic alterations that characterize neoplastic progression. Using a combination of high-throughput liquid-and-gas-chromatography-based mass spectrometry, we profiled more than 1,126 metabolites across 262 clinical samples related to prostate cancer (42 tissues and 110 each of urine and plasma). These unbiased metabolomic profiles were able to distinguish benign prostate, clinically localized prostate cancer and metastatic disease. Sarcosine, an N-methyl derivative of the amino acid glycine, was identified as a differential metabolite that was highly increased during prostate cancer progression to metastasis and can be detected non-invasively in urine. Sarcosine levels were also increased in invasive prostate cancer cell lines relative to benign prostate epithelial cells. Knockdown of glycine-N-methyl transferase, the enzyme that generates sarcosine from glycine, attenuated prostate cancer invasion. Addition of exogenous sarcosine or knockdown of the enzyme that leads to sarcosine degradation, sarcosine dehydrogenase, induced an invasive phenotype in benign prostate epithelial cells. Androgen receptor and the ERG gene fusion product coordinately regulate components of the sarcosine pathway. Here, by profiling the metabolomic alterations of prostate cancer progression, we reveal sarcosine as a potentially important metabolic intermediary of cancer cell invasion and aggressivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
A Direct Approach to False Discovery Rates
Storey, J. D. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00346 · Cited by 5,603
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Self-citationRole of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Self-citationKleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
Self-citationRegulation of Cell Motility by Mitogen-activated Protein Kinase
Klemke, R. L., Cai, S., Giannini, A. L., Gallagher, P. J., Lanerolle, P. D., & Cheresh, D. A. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.2.481 · Cited by 1,235
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Varambally, S., Cao, Q., Mani, R.-S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., et al. (2008) · Science · doi:10.1126/science.1165395 · Cited by 1,052
Self-citation[12] DNA arrays for analysis of gene expression
Eisen, M. B., & Brown, P. O. (1999) · Methods in Enzymology · doi:10.1016/s0076-6879(99)03014-1 · Cited by 1,032
Integrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922
Self-citation
Research works printed but not linked: 1
- Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002) · DOI · Paper page
Cited by
Items 101–120 of 120
Applications of metabolomics to study cancer metabolism
Kaushik, A. K., & DeBerardinis, R. J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.009 · Cited by 179
Metabolic response to iron deficiency in Saccharomyces cerevisiae
Shakoury-Elizeh, M., Protchenko, O., Berger, A., Cox, J., Gable, K., Dunn, T. M., Prinz, W. A., Bard, M., & Philpott, C. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091710 · Cited by 182
Self-citationA landscape of metabolic variation across tumor types
Reznik, E., Luna, A., Aksoy, B. A., Liu, E. M., La, K., Ostrovnaya, I., Creighton, C. J., Hakimi, A. A., & Sander, C. (2018) · Cell Systems · doi:10.1016/j.cels.2017.12.014 · Cited by 172
Sansbury, B. E., Cummins, T. D., Tang, Y., Hellmann, J., Holden, C. R., Harbeson, M. A., Chen, Y., Patel, R. P., Spite, M., Bhatnagar, A., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.266395 · Cited by 156
McMillan, A., Rulisa, S., Sumarah, M., Macklaim, J. M., Renaud, J., Bisanz, J. E., Gloor, G. B., & Reid, G. (2015) · Scientific Reports · doi:10.1038/srep14174 · Cited by 131
Gralka, E., Luchinat, C., Tenori, L., Ernst, B., Thurnheer, M., & Schultes, B. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.110536 · Cited by 128
Lin, Y., Ma, C., Liu, C., Wang, Z., Yang, J., Liu, X., Shen, Z., & Wu, R. (2016) · Oncotarget · doi:10.18632/oncotarget.8762 · Cited by 126
“As metabolites are present in readily-available biofluids, metabolomics has been applied to the diagnosis of many cancers, such as bladder [7], lung [8–10] and prostate [11].”
MethodPasikanti, K. K., Esuvaranathan, K., Hong, Y., Ho, P. C., Mahendran, R., Raman Nee Mani, L., Chiong, E., & Chan, E. C. Y. (2013) · Journal of Proteome Research · doi:10.1021/pr4000448 · Cited by 113
Current and future perspectives of functional metabolomics in disease studies–A review
Yan, M., & Xu, G. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.04.006 · Cited by 105
Glycine transport inhibitors in the treatment of schizophrenia
Javitt, D. C. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_12 · Cited by 83
Hu, L., Liu, J., Zhang, W., Wang, T., Zhang, N., Lee, Y. H., & Lu, H. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21611 · Cited by 81
Nikolic, S. B., Sharman, J. E., Adams, M. J., & Edwards, L. M. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000168 · Cited by 79
Lin, Y., Ma, C., Bezabeh, T., Wang, Z., Liang, J., Huang, Y., Zhao, J., Liu, X., Ye, W., Tang, W., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32190 · Cited by 57
Auslander, N., Yizhak, K., Weinstock, A., Budhu, A., Tang, W., Wang, X. W., Ambs, S., & Ruppin, E. (2016) · Scientific Reports · doi:10.1038/srep29662 · Cited by 50
Zhang, L., Niu, M., Wei, A.-W., Tang, J.-F., Tu, C., Bai, Z.-F., Zou, Z.-S., Xiao, X.-H., Liu, Y.-P., & Wang, J.-B. (2020) · Archives of Toxicology · doi:10.1007/s00204-019-02595-3 · Cited by 49
Personal phenotypes to go with personal genomes
Snyder, M., Weissman, S., & Gerstein, M. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.32 · Cited by 46
“Hundreds of metabolites can also be monitored using mass spectrometry (e.g. see Sreekumar et al, 2009).”
BackgroundPreoperative Metabolic Signatures of Prostate Cancer Recurrence Following Radical Prostatectomy
Clendinen, C. S., Gaul, D. A., Monge, M. E., Arnold, R. S., Edison, A. S., Petros, J. A., & Fernández, F. M. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00926 · Cited by 39
Computational Approaches in Theranostics: Mining and Predicting Cancer Data
Cova, T. F. G. G., Bento, D. J., & Nunes, S. C. C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030119 · Cited by 32
Epigenetic inactivation of PCDH10 in human prostate cancer cell lines
Li, Z., Li, W., Xie, J., Wang, Y., Tang, A., Li, X., Ye, J., Gui, Y., & Cai, Z. (2011) · Cell Biology International · doi:10.1042/cbi20100568 · Cited by 25
Reddy, P., Rochfort, S., Read, E., Deseo, M., Jaehne, E., Van Den Buuse, M., Guthridge, K., Combs, M., Spangenberg, G., & Quinn, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-45170-7 · Cited by 16
Metadata
- Authors
- Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., Nyati, M. K., Ahsan, A., Kalyana-Sundaram, S., Han, B., Cao, X., Byun, J., Omenn, G. S., Ghosh, D., Pennathur, S., Alexander, D. C., Berger, A., Shuster, J. R., Wei, J. T., Varambally, S., Beecher, C., & Chinnaiyan, A. M.
- Venue
- Nature
- Published
- 2009-02-01
- Volume
- 457
- Issue
- 7231
- Pages
- 910-914
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2155680682
- Cited by
- 2,234
- References
- 18
- FWCI
- 148.90
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-06-05)
- Open access
- bronze
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.